Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion
Year: 2013
Type: article
Study design: Case Report
Abstract: The advent of tyrosine kinase inhibitors (TKI) has profoundly changed the current therapeutic approach in some hematologic malignancies, including BCR-ABL1 -positive acute lymphoblastic leukemia (ALL). Recently, next-generation genomic methods have uncovered various alterations in ALL that lead to
Source: Haematologica
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W2004097969
